

Microba receives \$3 million R&D Tax Incentive Refund

Key Highlights

- \$3 million R&D Tax Incentive Refund received for Research & Development Activities conducted during FY25
- The FY25 R&D Tax Incentive adds to Microba's strong financial position of \$13.9 million in Cash or equivalents reported at the end of Q1 FY26

Microba Life Sciences Limited (ASX: MAP) ("Microba"), a company at the forefront of health and human care, is pleased to announce that the Company has received a \$3,063,625 Research & Development (R&D) Tax Incentive refund relating to R&D activities completed in the 2024/2025 financial year. The Australian Government's R&D Tax Incentive program provides companies with a 43.5% refundable tax offset for eligible R&D activities.

Microba's Chief Executive Officer, Dr. Luke Reid commented, "We sincerely appreciate the Australian Government's ongoing support through the R&D Tax Incentive. The program continues to be vital in assisting Microba to accelerate innovation across our gastrointestinal diagnostics portfolio and in FY25 to advance our clinical stage therapeutics pipeline. These research and development outputs are continuously being translated into our advanced clinical products, delivering transformative health outcomes and changing lives for thousands of people across Australia and the globe."

This announcement has been authorised for release by the Chair and CEO.

For further information, please contact:

Dr Luke Reid Chief Executive Officer luke.reid@microba.com

Investor / Media Relations investor@microba.com https://ir.microba.com/welcome

About Microba Life Sciences Limited

Microba is at the forefront of microbiome health and human care. With world-leading science, insights and collaboration tools, Microba's vision is to deliver clinical-grade microbiome tests that helps people live healthier, happier lives. Better science. Better insights. Better health. Microba - Expect better. www.microba.com

